92 related articles for article (PubMed ID: 20860475)
1. Chemotherapeutics of visceral leishmaniasis: present and future developments.
Sundar S; Singh A
Parasitology; 2018 Apr; 145(4):481-489. PubMed ID: 29215329
[TBL] [Abstract][Full Text] [Related]
2. Field safety and effectiveness of new visceral leishmaniasis treatment regimens within public health facilities in Bihar, India.
Goyal V; Mahajan R; Pandey K; Singh SN; Singh RS; Strub-Wourgaft N; Alves F; Rabi Das VN; Topno RK; Sharma B; Balasegaram M; Bern C; Hightower A; Rijal S; Ellis S; Sunyoto T; Burza S; Lima N; Das P; Alvar J
PLoS Negl Trop Dis; 2018 Oct; 12(10):e0006830. PubMed ID: 30346949
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment of recurrent visceral leishmaniasis relapse in an immunocompetent adult female with functional hypopituitarism in Bangladesh.
Hannan TB; Hossain Z; Roy U; Rahman SMM; Rahman MS; Sabah S; Rahat MA; Chowdhury R; Hossain F; Mondal D; Saha S; Haq T; Alam MR; Chowdhury FR
PLoS Negl Trop Dis; 2024 Apr; 18(4):e0012134. PubMed ID: 38669211
[TBL] [Abstract][Full Text] [Related]
4. Development of mannose-anchored thiolated amphotericin B nanocarriers for treatment of visceral leishmaniasis.
Shahnaz G; Edagwa BJ; McMillan J; Akhtar S; Raza A; Qureshi NA; Yasinzai M; Gendelman HE
Nanomedicine (Lond); 2017 Jan; 12(2):99-115. PubMed ID: 27879160
[TBL] [Abstract][Full Text] [Related]
5. A poor-quality generic drug for the treatment of visceral leishmaniasis: a case report and appeal.
Dorlo TP; Eggelte TA; Schoone GJ; de Vries PJ; Beijnen JH
PLoS Negl Trop Dis; 2012; 6(5):e1544. PubMed ID: 22666507
[No Abstract] [Full Text] [Related]
6. [Successful Treatment of Therapy-refractory Acanthamoeba Keratitis with Systemic Miltefosine and Topical Voriconazole].
Schwarzer P; Blaser F; Sellner M; Rauthe SC; Tandogan T; Tappeiner C; Goldblum D
Klin Monbl Augenheilkd; 2024 Apr; 241(4):406-408. PubMed ID: 38653269
[No Abstract] [Full Text] [Related]
7. The status of combination therapy for visceral leishmaniasis: an updated review.
van Griensven J; Dorlo TP; Diro E; Costa C; Burza S
Lancet Infect Dis; 2024 Jan; 24(1):e36-e46. PubMed ID: 37640031
[TBL] [Abstract][Full Text] [Related]
8. Clinical and experimental advances in treatment of visceral leishmaniasis.
Murray HW
Antimicrob Agents Chemother; 2001 Aug; 45(8):2185-97. PubMed ID: 11451673
[No Abstract] [Full Text] [Related]
9. More efficient ways of assessing treatments for neglected tropical diseases are required: innovative study designs, new endpoints, and markers of effects.
Olliaro P; Vaillant MT; Sundar S; Balasegaram M
PLoS Negl Trop Dis; 2012; 6(5):e1545. PubMed ID: 22666508
[No Abstract] [Full Text] [Related]
10. Need for sustainable approaches in antileishmanial drug discovery.
Hendrickx S; Caljon G; Maes L
Parasitol Res; 2019 Oct; 118(10):2743-2752. PubMed ID: 31473855
[TBL] [Abstract][Full Text] [Related]
11. Antileishmanial Activity of Disulfiram and Thiuram Disulfide Analogs in an Ex Vivo Model System Is Selectively Enhanced by the Addition of Divalent Metal Ions.
Peniche AG; Renslo AR; Melby PC; Travi BL
Antimicrob Agents Chemother; 2015 Oct; 59(10):6463-70. PubMed ID: 26239994
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of anti-leishmania therapy in visceral leishmaniasis among HIV infected patients: a systematic review with indirect comparison.
Cota GF; de Sousa MR; Fereguetti TO; Rabello A
PLoS Negl Trop Dis; 2013; 7(5):e2195. PubMed ID: 23658850
[TBL] [Abstract][Full Text] [Related]
13. Antileishmanial activity of diterpene acids in copaiba oil.
Santos AO; Izumi E; Ueda-Nakamura T; Dias-Filho BP; Veiga-Júnior VF; Nakamura CV
Mem Inst Oswaldo Cruz; 2013 Feb; 108(1):59-64. PubMed ID: 23440116
[TBL] [Abstract][Full Text] [Related]
14. Validation of a simple resazurin-based promastigote assay for the routine monitoring of miltefosine susceptibility in clinical isolates of Leishmania donovani.
Kulshrestha A; Bhandari V; Mukhopadhyay R; Ramesh V; Sundar S; Maes L; Dujardin JC; Roy S; Salotra P
Parasitol Res; 2013 Feb; 112(2):825-8. PubMed ID: 23239091
[TBL] [Abstract][Full Text] [Related]
15. Experimental induction of paromomycin resistance in antimony-resistant strains of L. donovani: outcome dependent on in vitro selection protocol.
Hendrickx S; Inocêncio da Luz RA; Bhandari V; Kuypers K; Shaw CD; Lonchamp J; Salotra P; Carter K; Sundar S; Rijal S; Dujardin JC; Cos P; Maes L
PLoS Negl Trop Dis; 2012; 6(5):e1664. PubMed ID: 22666513
[TBL] [Abstract][Full Text] [Related]
16. Integrated dataset of screening hits against multiple neglected disease pathogens.
Nwaka S; Besson D; Ramirez B; Maes L; Matheeussen A; Bickle Q; Mansour NR; Yousif F; Townson S; Gokool S; Cho-Ngwa F; Samje M; Misra-Bhattacharya S; Murthy PK; Fakorede F; Paris JM; Yeates C; Ridley R; Van Voorhis WC; Geary T
PLoS Negl Trop Dis; 2011 Dec; 5(12):e1412. PubMed ID: 22247786
[TBL] [Abstract][Full Text] [Related]
17. Leishmania antimony resistance: what we know what we can learn from the field.
Aït-Oudhia K; Gazanion E; Vergnes B; Oury B; Sereno D
Parasitol Res; 2011 Nov; 109(5):1225-32. PubMed ID: 21800124
[TBL] [Abstract][Full Text] [Related]
18. Treatment of visceral leishmaniasis in 2010: direction from Bihar State, India.
Murray HW
Future Microbiol; 2010 Sep; 5(9):1301-3. PubMed ID: 20860475
[No Abstract] [Full Text] [Related]
19. Anthropometrically derived dosing and drug costing calculations for treating visceral leishmaniasis in Bihar, India.
Olliaro P; Sundar S
Trop Med Int Health; 2009 Jan; 14(1):88-92. PubMed ID: 19121150
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
